Notes

1. de Vresse M, Stegelmann A, Richter B et al. Probiotics: compensation for lactase insufficiency. Am J Clin Nutr 2001;73(2Suppl):421S-29S. Texte intégral : www.ajcn.org/cgi/content/full/73/2/421S
2. Penner R, Fedorak RN, Madsen KL. Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. Curr Opin Pharmacol. 2005 Dec;5(6):596-603. Review.
3. Haddad PS, Azar GA, Groom S, Boivin M. Natural health products, modulation of immune function and prevention of chronic diseases. Evid Based Complement Alternat Med. 2005 Dec;2(4):513-20. Texte intégral : http://ecam.oxfordjournals.org
4. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials.J Pediatr Gastroenterol Nutr. 2001 Oct;33 Suppl 2:S17-25.
5. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev. 2004;(2):CD003048. Review.
6. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis.Pediatrics. 2002 Apr;109(4):678-84.
7. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci. 2002 Nov;47(11):2625-34.
8. Gaon D, Garcia H, Winter L, Rodriguez N, Quintas R, Gonzalez SN, Oliver G. Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children.Medicina (B Aires). 2003;63(4):293-8.
9. Surawicz CM, McFarland LV, Greenberg RN et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii.Clin Infect Dis. 2000 Oct;31(4):1012-7. Epub 2000 Oct 25.
10. McFarland LV, Surawicz CM, Greenberg RN et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.JAMA. 1994 Jun 22-29;271(24):1913-8.
11. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.Int Microbiol. 2004 Mar;7(1):59-62. Texte intégral : www.im.microbios.org
12. Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ. 2005 Jul 19;173(2):167-70. Review. Erratum in: CMAJ. 2005 Aug 16;173(4):345. Texte intégral : www.cmaj.ca
13. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis.BMJ. 2002 Jun 8;324(7350):1361. Texte intégral : http://bmj.bmjjournals.com
14. Cremonini F, Di Caro S, Nista EC, Bartolozzi F et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002 Aug;16(:1461-7. Review.
15. Szajewska H, Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2005 Sep 1;22(5):365-72. Review.
16. Hawrelak JA, Whitten DL, Myers SP. Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review. Digestion. 2005;72(1):51-6. Review.
17. Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, Lohse CM. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial.Mayo Clin Proc. 2001 Sep;76(9):883-9.
18. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients.J Infect. 1998 Mar;36(2):171-4.
19. La Rosa M, Bottaro G, Gulino N et al. [Prevention of antibiotic-associated diarrhea with Lactobacillus sporogens and fructo-oligosaccharides in children. A multicentric double-blind vs placebo study]. Minerva Pediatr. 2003 Oct;55(5):447-52. Italian.
20. Szajewska H, Kotowska M, Mrukowicz JZ, Armanska M, Mikolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants.J Pediatr. 2001 Mar;138(3):361-5.
21. Srinivasan R, Meyer R, Padmanabhan R, Britto J. Clinical Safety of Lactobacillus casei shirota as a Probiotic in Critically Ill Children. J Pediatr Gastroenterol Nutr. 2006 Feb;42(2):171-173.
22. Szajewska H, Mrukowicz JZ. Use of probiotics in children with acute diarrhea. Paediatr Drugs. 2005;7(2):111-22. Review.
23. Bleichner G, Blehaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial.Intensive Care Med. 1997 May;23(5):517-23.
24. Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.Gastroenterology. 2003 May;124(5):1202-9.
25. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.Gastroenterology. 2000 Aug;119(2):305-9.
26. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.Gut. 2004 Jan;53(1):108-14.
27. Gionchetti P, Amadini C, Rizzello F, Venturi A, Campieri M. Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther. 2002 Jul;16 Suppl 4:13-9.
28. Lammers KM, Vergopoulos A, Babel N et al. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. Inflamm Bowel Dis. 2005 May;11(5):447-54.
30. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003 Feb 15;17(4):509-15.
31. Laake KO, Bjorneklett A, Aamodt G et al. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol. 2005 Jan;40(1):43-51.
32. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.Aliment Pharmacol Ther. 1997 Oct;11(5):853-8.
33. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.Lancet. 1999 Aug 21;354(9179):635-9.
34. Kruis W, Fric P, Pokrotnieks et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004 Nov;53(11):1617-23.
35. Cui HH, Chen CL, Wang JD. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004 May 15;10(10):1521-5.
36. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis.Eur J Gastroenterol Hepatol. 2003 Jun;15(6):697-8.
37. Bibiloni R, Fedorak RN, Tannock GW et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005 Jul;100(7):1539-46.
38. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003 Feb;22(1):56-63.
39. Furrie E, Macfarlane S, Kennedy A et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005 Feb;54(2):242-9.
41. Salminen E, Elomaa I, Minkkinen J, Vapaatalo H, Salminen S. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures.
Clin Radiol. 1988 Jul;39(4):435-7.
42. Urbancsek H, Kazar T, Mezes I, Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea.Eur J Gastroenterol Hepatol. 2001 Apr;13(4):391-6.
43. Delia P, Sansotta G, Donato V et al.Prophylaxis of diarrhoea in patients submitted to radiotherapeutic treatment on pelvic district: personal experience. Dig Liver Dis. 2002 Sep;34 Suppl 2:S84-6.
44. Kalliomaki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial.Lancet. 2001 Apr 7;357(9262):1076-9.
45. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial.Lancet. 2003 May 31;361(9372):1869-71.
46. Viljanen M, Savilahti E, Haahtela T et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy. 2005 Apr;60(4):494-500.
47. Cross ML. Immunoregulation by probiotic lactobacilli: pro-Th1 signals and their relevance to human health Clin Appl Immunol Rev 2002; 3: 115-25. Cité dans : Haddad PS, Azar GA, Groom S, Boivin M. Natural health products, modulation of immune function and prevention of chronic diseases. Evid Based Complement Alternat Med. 2005 Dec;2(4):513-20. Texte intégral : http://ecam.oxfordjournals.org